| Source: |
Escherichia coli. |
| Molecular Weight: |
Approximately 20.0 kDa, containing 172 amino acid residues with two conserved disulfide bonds. |
| AA Sequence: |
CDLPQNHGLL SRNTLVLLHQ MRRISPFLCL KDRRDFRFPQ EMVKGSQLQK AHVMSVLHEM LQQIFSLFHT ERSSAAWNMT LLDQLHTGLH QQLQHLETCL LQVVGEGESA GAISSPALTL RRYFQGIRVY LKEKKYSDCA WEVVRMEIMK SLFLSTNMQE RLRSKDRDLG SS |
| Purity: |
> 97% by SDS-PAGE and HPLC analyses. |
| Biological Activity: |
Fully biologically active when compared to standard. The ED50 as determined by a chemotaxis bioassay using human TF-1 cells is less than 0.01 ng/mL, corresponding to a specific activity of > 1.0 × 108 IU/mg. |
| Physical Appearance: |
Sterile filtered white lyophilized (freeze-dried) powder. |
| Formulation: |
Lyophilized from a 0.2 µm filtered concentrated solution in PBS, pH7.4. |
| Endotoxin: |
Less than 1 EU/μg of rHuIFN-ω as determined by LAL method. |
| Reconstitution: |
Centrifuge the vial briefly before opening to ensure that the contents settle at the bottom. Reconstitute the vial with sterile distilled water or an aqueous buffer containing 0.1% BSA to achieve a concentration of 0.1-1.0 mg/mL. Divide the resulting stock solution into working aliquots and store them at or below -20°C. For further dilutions, use appropriate buffered solutions. |
| Stability & Storage: |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month, 2 to 8°C under sterile conditions after reconstitution.
3 months, -20 to -70°C under sterile conditions after reconstitution. |
| Synonyms: |
Interferon alpha-II-1 |
| Background: |
Interferon-Omega (IFN-ω), produced by the IFNW1 gene in humans, is one member of the type I interferon family, which also includes IFN-α, IFN-β, and IFN-ω. IFN-ω helps with signal transduction via the IFNAR-1/IFNAR-2 receptor complex, subsequent to its antiviral or antiproliferative activities. Sharing 75% of its sequence with IFN-α, IFN-ω is derived from IFN-α/β. Two intramolecular disulfide bonds are crucial for its activity. Bioassays for IFN-α, IFN-β, and IFN-ω designed by Mire-Sluis et al detail the ability of these factors to inhibit the TF-1 cell proliferation incited by GM-CSF. These bioassays can also be employed with Epo and TF-1 cells, or with Epo and Epo-transfected UT-7 cells. |
